Chemo Pharma Laboratories Ltd, a pharmaceutical company, has undergone significant changes in its leadership and corporate structure following its Annual General Meeting (AGM) held on September 24, 2025. The shareholders approved several key appointments and proposals that signal a new direction for the company.

New Leadership Appointments

The company has made strategic appointments to strengthen its executive team:

• Ruchit Mehta has been appointed as Managing Director & CEO, bringing over 4.50 years of experience in consultancy business and management.
• Utsav Trivedi takes on the role of Executive Director & CFO, with 2.00 years of experience in accounting and financial management.

Additionally, three new Independent Directors have joined the board:

• Sarvagya Goel, a Member of the Institute of Company Secretaries of India since 2016
• Shilpy Chopra, a Company Secretary with a B.Com degree
• Simran Tripathi, a Graduate and Inter Chartered Accountant

Auditor Appointments

The company has also made changes to its auditing team:

• M/s. Arvind Sudra & Associates has been appointed as Secretarial Auditors for the period 2025-2030.
• M/s. SSRV & Associates, Chartered Accountants, will serve as Statutory Auditors for the same period, filling a casual vacancy left by the resignation of the previous auditors.

Potential Name Change and Object Clause Alteration

In a significant move, shareholders approved a special resolution to change the company's name from "Chemo Pharma Laboratories Limited" to "STARSOURCE MULTITRADE LIMITED". This change, along with the approval to alter the Object Clause of the Memorandum of Association, suggests a potential shift in the company's business focus.

Reclassification of Promoter Group

The AGM also approved the reclassification of Shanta Somani from 'Promoter Group' Shareholder to 'Public' Shareholder, indicating changes in the company's ownership structure.

Voting Results

All resolutions presented at the AGM were passed with overwhelming majority, with each receiving 99.997% votes in favor.

Closure of Trading Window

Following the AGM, the company announced the closure of its trading window for designated persons from October 1, 2025, until two days after the announcement of the Q2 FY2026 financial results.

These developments mark a significant transition period for Chemo Pharma Laboratories, potentially setting the stage for a new chapter in the company's history. The appointment of a new leadership team, coupled with the proposed name change and object clause alteration, suggests that the company may be positioning itself for strategic changes in its business operations and focus.

Chemo Pharma Laboratories Limited, a pharmaceutical company listed on the Bombay Stock Exchange (BSE), has initiated the process to reclassify a member of its promoter group as a public shareholder. The company submitted an application to the BSE on September 10, 2025, seeking approval for this change in shareholder categorization.

Reclassification Details

The application pertains to Ms. Shanta Somani, who is currently classified as part of the Promoter Group. According to the company's filing:

• Shareholder: Ms. Shanta Somani
• Current Category: Promoter Group Shareholder
• Proposed Category: Public Shareholder
• Shareholding: 0 shares (0.00% of the company's equity)

Regulatory Compliance

The reclassification request has been made under Regulation 31A of the Securities and Exchange Board of India (SEBI) Listing Obligations and Disclosure Requirements (LODR) Regulations. This provision allows for the reclassification of promoters as public shareholders under specific conditions.

Company's Statement

In its official communication to the BSE, Chemo Pharma Laboratories stated:

"This is with reference with the captioned subject, and in compliance of Regulation 31A of SEBI LODR Regulations and amendment(s) thereto, we wish to inform you that the Company has made an application for approval to BSE Limited (BSE) on September 10, 2025 for reclassification of person forming part of the Promoter Group from 'Promoter Group Shareholder' category to 'Public Shareholder' category under the provisions of the SEBI LODR Regulations."

Implications

While the reclassification does not involve any change in Ms. Somani's shareholding, which stands at zero, it may have implications for the company's promoter group structure and regulatory reporting. The move could potentially affect the overall promoter holding percentage and the public float of the company's shares.

Investors and market participants will be watching for the BSE's decision on this application, as it may influence the perception of the company's ownership structure. The outcome of this reclassification request will be subject to regulatory scrutiny and approval from the stock exchange.